Q-omics provides the consensus-scored TRA2B profile across patient tissues and cancer cell-line models. TRA2B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRA2B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TRA2B protein abundance shows 31,125 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where TRA2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRA2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRA2B survival associations across molecular data types. TRA2B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRA2B RNA expression–survival associations across cancer types. High TRA2B expression shows unfavorable associations in ACC, LIHC, LGG, ESCA and LUAD, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRA2B RNA expression.
This table summarizes TRA2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRA2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRA2B shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, COAD and STAD. The HNSC box plot shows higher TRA2B RNA expression in tumor versus normal tissue (log2 FC = +0.785, t-test p < 0.001).
This table shows molecular features associated with TRA2B in patient tissues and cancer cell lines. In patient samples, TRA2B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRA2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
